Year |
Citation |
Score |
2021 |
Freyn AW, Han J, Guthmiller JJ, Bailey MJ, Neu K, Turner HL, Rosado VC, Chromikova V, Huang M, Strohmeier S, Liu STH, Simon V, Krammer F, Ward AB, Palese P, et al. Influenza hemagglutinin-specific IgA Fc-effector functionality is restricted to stalk epitopes. Proceedings of the National Academy of Sciences of the United States of America. 118. PMID 33593910 DOI: 10.1073/pnas.2018102118 |
0.56 |
|
2020 |
Wajnberg A, Amanat F, Firpo A, Altman DR, Bailey MJ, Mansour M, McMahon M, Meade P, Mendu DR, Muellers K, Stadlbauer D, Stone K, Strohmeier S, Simon V, Aberg J, et al. Robust neutralizing antibodies to SARS-CoV-2 infection persist for months. Science (New York, N.Y.). PMID 33115920 DOI: 10.1126/science.abd7728 |
0.372 |
|
2019 |
Broecker F, Zheng A, Suntrongwong N, Sun W, Bailey MJ, Krammer F, Palese P. Extending the stalk enhances immunogenicity of the influenza virus neuraminidase. Journal of Virology. PMID 31375573 DOI: 10.1128/Jvi.00840-19 |
0.542 |
|
2019 |
Broecker F, Liu STH, Suntronwong N, Sun W, Bailey MJ, Nachbagauer R, Krammer F, Palese P. A mosaic hemagglutinin-based influenza virus vaccine candidate protects mice from challenge with divergent H3N2 strains. Npj Vaccines. 4: 31. PMID 31341648 DOI: 10.1038/s41541-019-0126-4 |
0.539 |
|
2019 |
Bailey MJ, Broecker F, Freyn A, Choi A, Brown JA, Fedorova N, Simon V, Lim JK, Evans MJ, García-Sastre A, Palese P, Tan GS. Human monoclonal antibodies potently neutralize Zika virus and select for escape mutations on the lateral ridge of the envelope protein. Journal of Virology. PMID 31043537 DOI: 10.1128/Jvi.00405-19 |
0.569 |
|
2019 |
Bailey MJ, Broecker F, Duehr J, Arumemi F, Krammer F, Palese P, Tan GS. Antibodies Elicited by an NS1-Based Vaccine Protect Mice against Zika Virus. Mbio. 10. PMID 30940710 DOI: 10.1128/Mbio.02861-18 |
0.596 |
|
2018 |
Bailey MJ, Duehr J, Dulin H, Broecker F, Brown JA, Arumemi FO, Bermúdez González MC, Leyva-Grado VH, Evans MJ, Simon V, Lim JK, Krammer F, Hai R, Palese P, Tan GS. Human antibodies targeting Zika virus NS1 provide protection against disease in a mouse model. Nature Communications. 9: 4560. PMID 30385750 DOI: 10.1038/S41467-018-07008-0 |
0.615 |
|
2018 |
Bailey MJ, Broecker F, Leon PE, Tan GS. A Method to Assess Fc-mediated Effector Functions Induced by Influenza Hemagglutinin Specific Antibodies. Journal of Visualized Experiments : Jove. PMID 29553549 DOI: 10.3791/56256 |
0.425 |
|
2017 |
Leon PE, Wohlbold TJ, He W, Bailey MJ, Henry CJ, Wilson PC, Krammer F, Tan GS. Generation of Escape Variants of Neutralizing Influenza Virus Monoclonal Antibodies. Journal of Visualized Experiments : Jove. PMID 28872136 DOI: 10.3791/56067 |
0.442 |
|
2016 |
Mullarkey CE, Bailey MJ, Golubeva DA, Tan GS, Nachbagauer R, He W, Novakowski KE, Bowdish DM, Miller MS, Palese P. Broadly Neutralizing Hemagglutinin Stalk-Specific Antibodies Induce Potent Phagocytosis of Immune Complexes by Neutrophils in an Fc-Dependent Manner. Mbio. 7. PMID 27703076 DOI: 10.1128/Mbio.01624-16 |
0.551 |
|
2016 |
Leon PE, He W, Mullarkey CE, Bailey MJ, Miller MS, Krammer F, Palese P, Tan GS. Optimal activation of Fc-mediated effector functions by influenza virus hemagglutinin antibodies requires two points of contact. Proceedings of the National Academy of Sciences of the United States of America. PMID 27647907 DOI: 10.1073/Pnas.1613225113 |
0.546 |
|
2012 |
Blacksell SD, Jarman RG, Gibbons RV, Tanganuchitcharnchai A, Mammen MP, Nisalak A, Kalayanarooj S, Bailey MS, Premaratna R, de Silva HJ, Day NP, Lalloo DG. Comparison of seven commercial antigen and antibody enzyme-linked immunosorbent assays for detection of acute dengue infection. Clinical and Vaccine Immunology : Cvi. 19: 804-10. PMID 22441389 DOI: 10.1128/CVI.05717-11 |
0.394 |
|
2011 |
Blacksell SD, Jarman RG, Bailey MS, Tanganuchitcharnchai A, Jenjaroen K, Gibbons RV, Paris DH, Premaratna R, de Silva HJ, Lalloo DG, Day NP. Evaluation of six commercial point-of-care tests for diagnosis of acute dengue infections: the need for combining NS1 antigen and IgM/IgG antibody detection to achieve acceptable levels of accuracy. Clinical and Vaccine Immunology : Cvi. 18: 2095-101. PMID 22012979 DOI: 10.1128/CVI.05285-11 |
0.325 |
|
2008 |
Bailey MR, Chen D, Emery WR, Lambooy PK, Nolting J, Quertinmont MT, Shamlou PA. Evaluation of microfluidics reactor technology on the kinetics of virus inactivation. Biotechnology and Bioengineering. 99: 1384-91. PMID 18023056 DOI: 10.1002/Bit.21714 |
0.306 |
|
Show low-probability matches. |